Zafgen Issues Statement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death
October 16, 2015 1:28 PM EDTCowen reiterated an Outperform rating on Zafgen (NASDAQ: ZFGN), and cut the price target to $20.00 (from $60.00), following FDA'a decision to place beloranib on a partial clinical hold. Late yesterday ZFGN received verbal notice from the FDA that beloranib has been placed on partial... More
Zafgen (ZFGN) PT Lowered to $46 at RBC Capital; Discusses Road Ahead for Beloranib
October 15, 2015 7:17 AM EDTRBC Capital analyst Simos Simeonidis maintained an Outperform rating and lowered his price target on Zafgen (NASDAQ: ZFGN) to $46.00 (from $58.00) following a patient death. Simeonidi said while they expect near-term uncertainty, and obviously a very negative outcome is still possible, we see a couple of viable scenarios where none of what has transpired ends up leading to any real negative impact on ZFGN.
The analyst highlighted the following scenarios:
1) The patient death was on the placebo arm (best case scenario: drug's safety profile is "exonerated").... More
Leerink Partners Comments on Zafgen (ZFGN) Following Patient Death
October 14, 2015 2:26 PM EDTLeerink Partners analyst Joseph Schwartz weighed in on Zafgen (NASDAQ: ZFGN) after the company announced a patient death in the ongoing Phase III bestPWS study of beloranib in Prader-Willi Syndrome (PWS).
"This news, while negative, resolves the uncertainty and speculated negativity that... More
Zafgen (ZFGN) Worst Case Scenario Avoided, RBC Capital - Bloomberg
October 14, 2015 1:18 PM EDTZafgen (NASDAQ: ZFGN) has reversed and moved to the highs of the day following the announcement of a patient death.
RBC analyst said the worst case scenario has been avoided, according to Bloomberg headlines.
Shares are up 10%.
... MoreWho Traded Zafgen (ZFGN) on Illegal Insider Information?
October 14, 2015 12:54 PM EDTAfter days of speculation and a more 50% drop in its share price, Zafgen (NASDAQ: ZFGN) finally announced what the heck was going on. As expected, the news is not good.
Zafgen said it learned of a patient death in the ongoing Phase 3 bestPWS study of beloranib in Prader-Willi Syndrome, a rare genetic... More
Zafgen (ZFGN) will resume trading at 12:30pm ET
October 14, 2015 12:21 PM EDTZafgen (NASDAQ: ZFGN) will resume trading at 12:30pm EDT.
... MoreZafgen (ZFGN) Issues Statement; FDA Initiates Discussion Following Phase 3 bestPWS Death
October 14, 2015 12:01 PM EDTZafgen (NASDAQ: ZFGN) issued the following statement:
"Zafgen recently learned of a patient death which occurred in the Companys ongoing double-blind, randomized, placebo-controlled Phase 3 bestPWS study of beloranib in Prader-Willi Syndrome, a rare genetic disorder with a high rate of mortality linked... More
